Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPHGet Free Report) in a research note issued on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

NASDAQ BLPH opened at $0.07 on Friday. The stock has a market capitalization of $916,027.00, a PE ratio of -0.09 and a beta of 0.71. The business has a 50 day simple moving average of $0.06 and a two-hundred day simple moving average of $0.05. Bellerophon Therapeutics has a 1-year low of $0.03 and a 1-year high of $0.80.

Bellerophon Therapeutics Company Profile

(Get Free Report)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Read More

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.